Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1): A review
- PMID: 31499275
- DOI: 10.1016/j.critrevonc.2019.08.003
Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1): A review
Abstract
Early stage (T1-2, N0-1) oral squamous cell carcinoma (OSCC) has a generally favorable prognostic outcome. However, locoregional recurrences can occur in up to 30-35% of patients, and 20% will eventually die of disease. National and international treatment guidelines do not recommend the use of postoperative radiotherapy (PORT) in a setting of early OSCC, and highlight surgery alone as the standard single modality treatment. Notwithstanding, the negative prognostic impact of some adverse pathological features, such as perineural and lymphovascular invasion, poor differentiation, depth of invasion >4 mm, and presence of nodal metastasis, is well known. The advantages of PORT in such scenarios are still debated. The aim of this study was to review the more recent literature to provide evidence on the benefits of PORT in the context of early stage OSCC.
Keywords: Adverse pathological feature; Early stage oral cavity cancer; Postoperative radiotherapy.
Copyright © 2019. Published by Elsevier B.V.
Similar articles
-
Postoperative Observation Versus Radiotherapy for Pathologic N1 Oral Cavity Squamous Cell Carcinoma.Am J Clin Oncol. 2021 Mar 1;44(3):99-104. doi: 10.1097/COC.0000000000000792. Am J Clin Oncol. 2021. PMID: 33417322
-
A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.BMC Cancer. 2020 Aug 5;20(1):730. doi: 10.1186/s12885-020-07231-3. BMC Cancer. 2020. PMID: 32758188 Free PMC article. Clinical Trial.
-
Predictors of locoregional control in stage I/II oral squamous cell carcinoma classified by AJCC 8th edition.Eur J Surg Oncol. 2019 Nov;45(11):2126-2130. doi: 10.1016/j.ejso.2019.05.018. Epub 2019 May 18. Eur J Surg Oncol. 2019. PMID: 31196702
-
Adverse pathologic features in early oral squamous cell carcinoma and the role of postoperative radiotherapy-a review.Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Jul;124(1):24-31. doi: 10.1016/j.oooo.2017.03.002. Epub 2017 Mar 10. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017. PMID: 28506568 Review.
-
Impact of Adjuvant Radiotherapy in Squamous Cell Carcinoma of the Oral Cavity with Perineural Invasion.Laryngoscope. 2024 May;134(5):2019-2027. doi: 10.1002/lary.31148. Epub 2023 Nov 17. Laryngoscope. 2024. PMID: 37975480 Review.
Cited by
-
The effect of postoperative adjuvant chemotherapy on survival outcomes in patients with early stage oral squamous cell carcinoma.Sci Rep. 2025 Jul 25;15(1):27157. doi: 10.1038/s41598-025-11565-y. Sci Rep. 2025. PMID: 40715317 Free PMC article.
-
Intraoral ultrasonography in the assessment of DOI in oral cavity squamous cell carcinoma: a comparison with magnetic resonance and histopathology.Eur Arch Otorhinolaryngol. 2021 Aug;278(8):2943-2952. doi: 10.1007/s00405-020-06421-w. Epub 2020 Oct 21. Eur Arch Otorhinolaryngol. 2021. PMID: 33084951 Free PMC article.
-
Clinicopathological characteristics, treatment and prognosis of oral adenocarcinoma: a population-based study.Eur Arch Otorhinolaryngol. 2023 Jul;280(7):3365-3374. doi: 10.1007/s00405-023-07912-2. Epub 2023 Mar 9. Eur Arch Otorhinolaryngol. 2023. PMID: 36892615
-
Risk Classification of Oral Cancer Surgical Margins: Margin to Depth of Invasion Ratio Analysis.Ann Surg Oncol. 2025 Jul;32(7):5230-5242. doi: 10.1245/s10434-025-17286-w. Epub 2025 Apr 23. Ann Surg Oncol. 2025. PMID: 40268847
-
Adjuvant brachytherapy for oral squamous cell carcinomas: a single-center experience comparing low-dose and pulsed-dose-rate techniques.Strahlenther Onkol. 2022 Feb;198(2):150-158. doi: 10.1007/s00066-021-01870-6. Epub 2021 Nov 16. Strahlenther Onkol. 2022. PMID: 34786604
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical